Financial Performance - Worldwide Baxter sales from continuing operations grew by 5% on both a reported and operational basis[16] - Adjusted earnings per share from continuing operations totaled $055, exceeding the original guidance of $047 to $050 per diluted share[16] - Adjusted diluted EPS increased by 53% year-over-year, from $036 in Q1 2024 to $055 in Q1 2025[18, 21, 23] - Global reported sales increased from $25 billion in Q1 2024 to $26 billion in Q1 2025, representing a 5% increase[21] - Adjusted operating margin increased by 260 bps, from 123% in Q1 2024 to 149% in Q1 2025[21, 23] Segment Performance - Medical Products & Therapies net sales increased by 3%, from $1229 million in Q1 2024 to $1262 million in Q1 2025[34] - Healthcare Systems & Technologies net sales increased by 6%, from $667 million in Q1 2024 to $704 million in Q1 2025[36] - Pharmaceuticals net sales increased by 1%, from $578 million in Q1 2024 to $581 million in Q1 2025[38] 2025 Outlook - The company expects full-year 2025 operational sales growth from continuing operations to be 4%-5%[44] - The company expects full-year 2025 adjusted diluted EPS from continuing operations to be $247-$255[44]